Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.34
- Piotroski Score 1.00
- Grade Outperform
- Symbol (CYT)
- Company Cyteir Therapeutics, Inc.
- Price $3.02
- Changes Percentage (-2.27%)
- Change -$0.07
- Day Low $3.00
- Day High $3.09
- Year High $3.19
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.
- Last Earnings 10/16/2015
- Ex-Dividend for 5/16 Dividend 11/06/2015
- Dividend Payable 11/25/2015
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $2.00
- High Stock Price Target $2.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.93
- Trailing P/E Ratio -3.247311827957
- Forward P/E Ratio -3.247311827957
- P/E Growth -3.247311827957
- Net Income $-43,952,000
Income Statement
Quarterly
Annual
Latest News of CYT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History
Bayer has acquired rights to Cytokinetics' heart drug in Japan through a collaboration deal. The agreement includes an upfront payment of 50 million euros with potential additional payments based on d...
By Yahoo! Finance | 2 days ago -
Bayer acquires rights to Cytokinetics' heart drug in Japan
Bayer collaborates with U.S. biotech firm Cytokinetics to acquire rights in Japan for an experimental heart drug, strengthening its cardiovascular business. The deal includes upfront payment of 50 mil...
By Yahoo! Finance | 2 days ago -
Here's How Jakafi's Patent Expiry Impacts Incyte Corporation's (INCY) Growth Prospects
Incyte Corporation is preparing for Jakafi's patent expiry in 2028, focusing on growth beyond that period. With innovative therapies and a diverse product pipeline, including Opzelura and other promis...
By Yahoo! Finance | 5 days ago
